Latest Conference Articles

June 30th 2017, 6:55pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Monotherapy with potent BRAF inhibitor dabrafenib (Tafinlar) resulted in a disease control rate of 83% in patients with BRAF-mutant melanoma and brain metastases.

June 30th 2017, 5:49pm

State of the Science Summit on Melanoma and Immuno-Oncology

Anna C. Pavlick, DO, discusses adjuvant therapy for patients with high-risk melanoma.

June 30th 2017, 5:29pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.

June 30th 2017, 5:27pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.

June 30th 2017, 3:25am

European Post-Chicago Melanoma / Skin Cancer Meeting

Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.

June 30th 2017, 3:07am

European Post-Chicago Melanoma / Skin Cancer Meeting

Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.

June 30th 2017, 1:36am

ESMO Gastrointestinal Cancers Congress

Julien Taieb, MD, discusses the prognostic value of primary tumor location in colon cancer.

June 30th 2017, 1:02am

State of the Science Summit on Melanoma and Immuno-Oncology

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

June 30th 2017, 12:05am

State of the Science Summit on Melanoma and Immuno-Oncology

Melissa A. Wilson, MD, PhD, discussed the promising results with BRAF/MEK inhibitor combinations in melanoma and what ongoing studies have the potential to alter the landscape again.

June 29th 2017, 10:24pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.

June 29th 2017, 10:00pm

ESMO Gastrointestinal Cancers Congress

The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.

June 29th 2017, 9:55pm

ESMO Gastrointestinal Cancers Congress

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

June 29th 2017, 9:51pm

ESMO Gastrointestinal Cancers Congress

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma.

June 29th 2017, 9:32pm

ESMO Gastrointestinal Cancers Congress

Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) demonstrated encouraging clinical activity in metastatic pancreatic ductal adenocarcinoma.

June 29th 2017, 8:28pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.

June 29th 2017, 3:14pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.

June 27th 2017, 12:30am

European Hematology Association Congress

The first known trial of combined ublituximab (TG-1101), ibrutinib (Imbruvica), and umbralisib (TGR-1202) showed that the combination was well tolerated and had activity across heavily pretreated patients with high-risk B-cell malignancies.

June 26th 2017, 8:42pm

European Hematology Association Congress

Combination ibrutinib (Imbruvica) and venetoclax (Venclexta) set the bar high and aims to achieve eradication of minimal residual disease within a year of treatment in patients with relapsed or refractory chronic lymphocytic leukemia.

June 25th 2017, 11:54pm

European Hematology Association Congress

The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

June 25th 2017, 10:19pm

European Hematology Association Congress

Matthew J. Matasar, MD, discusses the potential of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.